Skip to main content

Security report for biogen.be

Biogen Belgium SA · Healthcare · Belgium

Low risk. 3 critical or high findings in Email security, SSL/TLS and 1 other check.

Security score

76/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Belgium SA operates as a regional branch of the global biotechnology leader Biogen Inc., focusing on innovative therapies in neurology, neuropsychiatry, immunology, and rare diseases. The website targets healthcare professionals and patients in Belgium and Luxembourg, providing corporate information, therapeutic areas, and career opportunities. The digital infrastructure is built on Adobe Experience Manager with modern JavaScript libraries and integrates Google Analytics and Cookiebot for privacy compliance. Security posture is strong with HTTPS and secure cookies, though explicit security policies and incident response details are absent. The WHOIS data is restricted, common for .be domains, but the website's professional presentation and consistent branding support legitimacy. Overall, the site demonstrates a mature digital presence aligned with corporate standards.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

  3. DNS health

    DNS sends visitors and email to the right servers. Misconfigured records can cause outages or let someone redirect your traffic.

    • High

      Unregistered MX Record

      MX record points to unregistered domain: mail

      What to do: Remove or fix MX record pointing to unregistered domain

      • RFC 5321 §5.1
      • NIS2 21(2)(i)
      • IR 2024/2690 12.4: Implementing Regulation (EU) 2024/2690, Annex point 12.4: Asset inventory
      • NIST CM-8: NIST SP 800-53 Rev. 5 CM-8: System Component Inventory

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.be

This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
45
Network security
100
GDPR outside view
83
Average
76

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Belgium SA holds a strong market position as a pioneer in biotechnology and neurological disease treatment. The business model centers on research, development, and commercialization of therapies, supported by a global parent company. The website reflects a focus on compliance, patient and professional engagement, and corporate responsibility. The presence of multiple regional domains indicates a broad partnership and subsidiary ecosystem. The company targets healthcare sectors with specialized therapies, emphasizing innovation and patient care. Growth indicators include active career recruitment and comprehensive corporate responsibility content.

Security posture

The website enforces HTTPS with secure, HttpOnly cookies and implements a cookie consent mechanism compliant with GDPR. However, it lacks explicit security headers such as Content Security Policy, HSTS, and X-Frame-Options, which are recommended to enhance protection against common web attacks. No vulnerability disclosure or incident response information is published, which could improve transparency and trust. No exposed sensitive data or vulnerable libraries were detected. Overall, the security posture is solid but could benefit from additional best practices and published policies.

Recommendations

  1. Implement and publish a formal security policy and incident response plan on the website.
  2. Add security headers including Content Security Policy (CSP), HTTP Strict Transport Security (HSTS), and X-Frame-Options.
  3. Establish a vulnerability disclosure program and publish security.txt to improve transparency.
  4. Provide direct contact information for security incidents or data protection officer to enhance trust.
  5. Regularly audit and update third-party libraries and scripts to mitigate potential vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Belgium SA
Description
Biogen est une entreprise de premier plan dans le domaine de la biotechnologie à l'échelle mondiale, se démarquant par son rôle de pionnière dans la recherche scientifique et l'innovation pour traiter des maladies complexes et dévastatrices. Biogen se consacre au développement de diverses thérapies potentielles dans les domaines de la neurologie, de la neuropsychiatrie, de l'immunologie spécialisée et des maladies rares, tout en demeurant profondément engagée dans sa mission de servir l'humanité grâce à la science, oeuvrant ainsi pour un monde plus sain, durable et équitable.
Key services
Research and development of therapies, Patient support, Healthcare professional resources
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HttpOnly cookies used
  • Cookie consent mechanism

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content in French targeting Belgium and Luxembourg.
  2. Strong corporate branding consistent with Biogen global identity.
  3. Comprehensive cookie and privacy policies with consent mechanisms implemented.
  4. No direct contact emails or phone numbers found; contact via web forms only.
  5. No explicit security policy or incident response information published.
  6. Modern technology stack with Adobe Experience Manager CMS and standard analytics.
  7. No suspicious or malicious content detected.
  8. WHOIS data is restricted, limiting domain registration transparency.
Technical notes

Notes

The website uses Adobe Experience Manager CMS, a robust enterprise platform, combined with modern JavaScript libraries like jQuery 3.6.4 and Adobe Helix RUM for performance monitoring. Google Tag Manager and Google Analytics are integrated for analytics and marketing. The site is mobile responsive with good SEO and accessibility basics. Performance is moderate, with room for optimization. The technical stack is modern and suitable for a large enterprise, though some improvements in accessibility and security headers could enhance overall quality and risk posture.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.be. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.be.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.